FibroGen Inc (NASDAQ:FGEN) SVP Christine Chung sold 5,625 shares of the stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $45.98, for a total value of $258,637.50. Following the sale, the senior vice president now owns 138,269 shares in the company, valued at approximately $6,357,608.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Christine Chung also recently made the following trade(s):
- On Monday, January 6th, Christine Chung sold 5,625 shares of FibroGen stock. The stock was sold at an average price of $42.98, for a total value of $241,762.50.
- On Monday, December 16th, Christine Chung sold 5,625 shares of FibroGen stock. The stock was sold at an average price of $47.08, for a total value of $264,825.00.
NASDAQ:FGEN opened at $44.51 on Friday. FibroGen Inc has a 1-year low of $32.33 and a 1-year high of $61.23. The business’s 50-day moving average price is $43.37 and its two-hundred day moving average price is $42.26. The company has a current ratio of 9.01, a quick ratio of 8.95 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $3.80 billion, a price-to-earnings ratio of 114.13 and a beta of 1.95.
FibroGen (NASDAQ:FGEN) last released its earnings results on Monday, November 11th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.02. FibroGen had a return on equity of 7.33% and a net margin of 11.81%. The firm had revenue of $33.17 million for the quarter, compared to analyst estimates of $31.61 million. During the same quarter in the prior year, the firm posted ($0.50) earnings per share. The company’s quarterly revenue was up 14.3% on a year-over-year basis. Sell-side analysts predict that FibroGen Inc will post -0.28 earnings per share for the current year.
A number of large investors have recently added to or reduced their stakes in the business. Banco Bilbao Vizcaya Argentaria S.A. acquired a new position in FibroGen in the fourth quarter valued at about $551,000. Oxford Asset Management LLP lifted its stake in FibroGen by 95.0% in the fourth quarter. Oxford Asset Management LLP now owns 32,401 shares of the biopharmaceutical company’s stock valued at $1,390,000 after buying an additional 15,786 shares during the period. Amalgamated Bank lifted its stake in FibroGen by 6.0% in the fourth quarter. Amalgamated Bank now owns 14,343 shares of the biopharmaceutical company’s stock valued at $615,000 after buying an additional 814 shares during the period. Farallon Capital Management LLC lifted its stake in FibroGen by 35.0% in the fourth quarter. Farallon Capital Management LLC now owns 1,350,000 shares of the biopharmaceutical company’s stock valued at $57,902,000 after buying an additional 350,000 shares during the period. Finally, Virtus ETF Advisers LLC lifted its stake in FibroGen by 41.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 8,823 shares of the biopharmaceutical company’s stock valued at $378,000 after buying an additional 2,604 shares during the period. 68.39% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages have recently commented on FGEN. Zacks Investment Research upgraded FibroGen from a “hold” rating to a “strong-buy” rating and set a $48.00 target price on the stock in a report on Thursday, January 30th. BidaskClub upgraded FibroGen from a “sell” rating to a “hold” rating in a report on Wednesday, February 5th. Mizuho restated a “buy” rating and set a $72.00 target price on shares of FibroGen in a report on Thursday. Finally, ValuEngine upgraded FibroGen from a “hold” rating to a “buy” rating in a report on Friday, January 3rd. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $51.25.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Recommended Story: How can investors find ex-dividend dates?
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.